Effect of bone marrow derived mononuclear cells in treatment of pediatric with cardiomyopathy

Safety Assessment of Intracoronary Transplantation of Autologous Bone Marrow Derived Mononuclear Cells in Pediatric with Dilated Cardiomyopathy in Comparison with Control Group: Clinical Trial Phase I/II

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20080728001031N27

Enrollment

Registered

2021-01-10

Start date

2013-05-01

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dilated cardiomyopathy. Dilated cardiomyopathy

Interventions

Intervention 1: Intervention group: This group underwent bone marrow aspiration in amount of 2 cc/kg. This sample transfers to clean room of Royan institute for mononuclear cells processing. Then, pat

Eligibility

Sex/Gender

All

Age

1 Years to 16 Years

Inclusion criteria

Inclusion criteria: LVEF 3m Resistance to Standard therapy > 1m (Dig, ACE, Diuretic, BB)

Exclusion criteria

Exclusion criteria: Critical aortic stenosis Severe coarctation Coronary artery anomalies Cardiogenic shock

Design outcomes

Primary

Measure	Time frame
Assessment of safety and tolerability. Timepoint: 3 months. Method of measurement: Physical examination and clinical symptom.	—

Secondary

Measure	Time frame
ProBNP measurement. Timepoint: 0, 2 weeks, 1, 2, 4 and 6 months. Method of measurement: Lab test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHoda Madani

Royan Institute

hoda62_m@yahoo.com+98 21 2251 8388

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026